Mechanisms of secondary resistance to imatinib in gastrointestinal stromal tumors / 国际肿瘤学杂志

ABSTRACT

Imatinib is an effective tyrosine kinase inhibitor, used in the treatment of advanced or inoperable gastrointestinal stromal tumors. Despite its efficacy, resistance is often developed among a portion of patients. Resistance to imatinib can be divided into primary and secondary resistance, with the latter becoming the focus of many recent researches. Research on the mechanisms of secondary resistance may lead to the identification of novel therapeutic strategies.